Objective. This study investigated for whom interdisciplinary pain management (IPM) is most effective. Identification of predictors of treatment responsivity would facilitate development of patient-treatment matching algorithms to optimize outcomes.
Subjects. A total of 163 adults referred for chronic pain management.
Methods. Self-report questionnaires and measures of physical performance were obtained at program entry and completion. Group-level analyses were performed using standard parametric statistics. Individual-level change was assessed using recommended criteria. Multivariate analysis of variance and logistic regression were used to examine outcomes and predictors of response.
Results. Significant improvements were observed across psychological, social, and physical outcome domains. Up to 50% of participants had clinically meaningful improvements, while less than 10% deteriorated. Higher baseline depression, anxiety, stress, and pain catastrophizing scores predicted better group-level outcomes (Ps < 0.05). Participants with higher baseline depression scores were most likely to show significant individual-level improvement on at least one outcome (Ps < 0.05). Participants with nociceptive pain were more than four times more likely than those with neuropathic pain to show clinically meaningful improvement on multiple outcomes, while those participants who were older were more likely to be multidomain responders.
Introduction
Chronic pain conditions are by their nature heterogeneous and often intractable to treatment. Interdisciplinary pain management (IPM) is considered best practice for managing chronic pain and for minimizing its personal and societal cost [1] . IPMs typically comprise several disciplines, working closely together within a single program to achieve common goals [2] . While some participants respond very well, reported IPM group effect sizes are modest and are attenuated by nonresponders [3] [4] [5] .
In order to optimize outcomes and to make more efficient use of resource-intensive IPM programs, there is a need to determine for whom they are most likely to be beneficial. The limited available research suggests that females report better outcomes than males, although results are mixed [6, 7] , and that differential outcomes are also influenced by age, baseline pain intensity, pain duration, number of pain sites, pain type, pain catastrophizing, and emotional distress [8] . However, this research has predominantly examined predictors of treatment responsivity on the basis of group-level statistics.
Closer investigation of the defining characteristics of those individuals who show clinically meaningful improvement and those who worsen during IPM would further our capacity to develop patient-treatment matching algorithms to enhance outcomes and optimize the use of scarce and expensive resources. A recent systematic investigation by Fedoroff et al. failed to find significant individual-level predictors of treatment responders [9] . However, the psychological variables that they studied did not include pain catastrophizing, anxiety, or stress, and they included only one painrelated physical performance measure.
The present study of a community-based IPM program employed similar criteria of group and individual responsiveness to those used by Fedoroff et al. [9, 10] . In addition, we examined a wider range of patient variables and outcome measures. The specific aims of the current study were two-fold. Aim 1 was to examine groupand individual-level outcomes during an IPM program. It was expected that statistically significant group-level improvements in outcomes would emerge and that clinically reliable measures of individual responsivity would be identified. Aim 2 was to empirically investigate key patient characteristics (as identified in previous literature) that could potentially predict group and/or individual responsiveness to an IPM program. It was expected that statistically significant predictors of group-level improvements in pain-related outcomes would emerge and that the use of individual-level outcome classification methods would provide clinically useful indications of what patient characteristics are associated with improved outcome from an IPM program.
Materials and Methods

Design
A repeated measures prospective study of consecutive admissions who completed a community-based IPM program was undertaken. Multiple self-report and objective measures were obtained, and medical chart review was conducted. This research was approved by the University of Queensland Behavioural and Social Sciences Ethical Review Committee and the Canossa Hospital Board, and written informed consent was obtained from all participants before participation.
Participants
We analyzed data from 163 adults with heterogeneous chronic pain conditions who were consecutive admissions (between January 2012 and June 2014) to the IPM program of the Brisbane Pain and Rehabilitation Service at Canossa Private Hospital in Brisbane, Queensland, Australia. A further 10 individuals dropped out of the program, and their data were not included in the analyses due to ethical restrictions. Participants were referred by health care providers or community and government agencies, or they were self-referred on occasion.
Measures
Medical assessments were undertaken by rehabilitation physicians, psychosocial self-reports were administered by psychologists, and physical performance measures were conducted by physical therapists. Clinical assessors were blind to the research aims and hypotheses. The following measures were performed on entry and at the conclusion of the program.
Chronic Pain Grade
The seven-item Chronic Pain Grade Questionnaire (CPG) was used to classify the nature of the chronic pain symptoms [11] . The CPG assesses pain on the dimensions of persistence, intensity, and disability and classifies patients into five hierarchical grades: grade 0 (pain free), grade I (low disability, low intensity), grade II (low disability, high intensity), grade III (high disability, moderately limiting), and grade IV (high disability, severely limiting). This questionnaire has been found to be a valid instrument for measuring severity of chronic pain [11, 12] .
Pain Intensity
An 11-point numerical rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine) was used to assess current pain intensity, as recommended by current guidelines [13] . The NRS has been shown to be a valid measure of pain intensity that has demonstrated superior responsivity compared with a visual analog scale, verbal rating scale, and the faces pain scale-revised [14] . A 30% or greater decrease in pain intensity has been identified as indicating clinically meaningful change [10] , and this criterion was implemented in the current study.
Pain Catastrophizing
The Pain Catastrophizing Scale (PCS) is a 13-item measure that asks respondents to rate, on a five-point Likert scale (0 ¼ not at all to 4 ¼ all the time), the degree to which they have certain thoughts and feelings when experiencing pain [15] . Higher scores indicate greater use of catastrophic thinking in response to pain. The PCS has exhibited strong internal consistency (a ¼ 0.93) and concurrent and discriminant validity [15, 16] . The PCS has demonstrated high test-retest reliability over a six-week period (r ¼ 0.75), which was used in calculations of the reliable change index (RCI) in the current study [15, 16] .
Emotional Functioning
The Depression Anxiety Stress Scales (21-item version; DASS-21) was administered to assess emotional distress on a four-point scale (0 ¼ never to 3 ¼ almost always). The original DASS contains 42 items; however, the DASS-21 has similar psychometric properties and is as effective a measure as the original [17] . The subscales discriminate between depression, anxiety, and stress, and have high internal consistency [18] . The test-retest reliabilities of the 42-item DASS [19] were used as proxies for the 21-item version (depression: r ¼ 0.71; anxiety: r ¼ 0.79; stress: r ¼ 0.81) for stability estimates used in the RCI calculations.
Psychosocial Functioning
The Outcome Questionnaire-45 (OQ-45) contains 45 items rated on a five-point scale that assesses psychosocial functioning across three domains: symptom distress, interpersonal relationships, and social functioning. The OQ-45 has demonstrated adequate internal consistency (r ¼ 0.93), and concurrent validity is moderate to high (r values of 0.50-0.85) [20] . Test-retest reliability has been shown to be adequate for the symptom distress (r ¼ 0.78), interpersonal relationships (r ¼ 0.80), and social functioning (r ¼ 0.82) scales [20] , and these published psychometric data were used to calculate the RCI in this study.
Physical Functioning
The Timed Up and Go (TUG) test measures the time it took participants to rise from a standard chair (46-cm seat height from the ground), walk a distance of 3 meters, turn around, walk back to the chair, and sit down [21] . The TUG has been shown to be a valid and reliable measure for quantifying functional mobility [21] . Test-retest reliability of the TUG has been shown to be high (r ¼ 0.99) [22] , and these data were used to calculate the RCI in the current research.
Grip strength was measured bilaterally in a seated position using a Saehan Hydraulic Hand Dynamometer [23] . Both hands were tested three times, with the highest value recorded to characterize the grip strength of each hand of the participant. A 30-second rest was given between testing of the same hand. Test-retest reliability for the right and left hands (r ¼ 0.78 and 0.87, respectively) has been shown to be adequate [24] and was used to calculate the RCI in the current analyses.
The 6-Minute Walk (6MW) test was conducted to assess functional exercise capacity. It has been shown to be a valid and useful measure for this purpose [25] , with high (r ¼ 0.98) test-retest reliability [22] ; it was used for RCI calculation in this study. Participants were asked to walk laps of a 20-meter course. Participants were instructed to walk at their own pace while attempting to cover as much ground as possible in the allotted time period of six minutes, and standardized encouragement was provided every 30 seconds [26] .
The One-Legged Stance (OLS) test with eyes closed was used to evaluate the ability to maintain static balance. It has been shown to be a valid and reliable tool, with adequate test-retest reliability (r ¼ 0.74) for the eyes-closed format of the test [27] . The OLS test was performed with the patient in the standing position with arms by their side. The test was performed on each leg with eyes open first, followed by eyes closed, with the best of three attempts with eyes closed recorded for data analysis.
The Two-Minute Stair Climb test was conducted to assess aerobic endurance. This has been shown to be a reliable and valid assessment tool for people with chronic pain [24] . The test-retest reliability of the stair climb test (r ¼ 0.94) is high [24] , and these data were used to calculate the RCI in the current analyses.
Therapeutic Procedures
These were delivered in group format over a two-week period, which is the standard treatment length for intensive rehabilitation programs in the Australian health care setting. A clinic procedures manual was used to ensure standardization of treatment content and intensity of care across all programs. The same core interdisciplinary team was in place throughout the period of data collection.
There were six to 10 patients in each program, and all participants received the same treatment protocol, with some individual customization (described below), delivered by rehabilitation physicians, physiotherapists, occupational therapists, psychologists, and dietitians. Participants attended daily sessions (excluding Sundays) for six hours (excluding tea and lunch breaks). The program included physical therapy, exercise therapy, occupational therapy, manualized cognitive behavioral therapy, analgesic medication tapering (when indicated), and nutrition and pain education.
Within the standard procedures, physical therapy programs were individualized for each participant according to their baseline physical strengths and weaknesses. During the program, 30% of the sample had medication changes (usually reduction in analgesics). In addition, 31% received local injections (e.g., cortisone), and 28% of the sample had a consultation with the psychiatrist on the IPM team.
The initial medical admission focused on gaining an understanding of the underlying medical condition, previous management attempts (including medication), and current rehabilitation needs. A group educational session was provided on pain medication, aimed at minimizing the use of opioids and other analgesic medications with abuse and misuse potential.
The physiotherapy and exercise physiology component of the program began with an individual intake assessment to obtain baseline functional measures and to customize the therapeutic exercise program. Individual programs were then written in conjunction with the patient, depending on their capacity to continue these forms of exercise after the program. The program contained four major elements: condition-specific therapeutic exercises, self-management techniques, general physical conditioning in a gymnasium, and hydrotherapy. Participants followed their individualized programs each day for 1.5 hours within a group session overseen by physical therapists. An understanding of how pain can alter muscle function was discussed in accompanying group seminars.
The psychology component of the program consisted of an individual intake session where baseline pain intensity and psychosocial functioning were assessed, an individual midpoint session to discuss progress and review goals and potential challenges, and six 1.5-hour manualized group sessions. The first psychology group session contained psychoeducation on the chronic pain cycle and the relationship between stress management and pain. Coping strategies of controlled deep breathing and progressive muscle relaxation were taught and practiced in this and succeeding sessions. Participants were provided with a CD recording of the relaxation technique for their own personal use. Session 2 focused on psychoeducation regarding sleep and pain and the use of self-administered analgesics. Evidence-based sleep hygiene was taught, and assigned homework included practice at changing sleep habits to improve sleep hygiene. Session 3 contained exercises on mindfulness, acceptance, and values-based action stemming from an acceptance and commitment therapy framework. Sessions 4 and 5 contained traditional cognitive behavioral therapy techniques, including identification of negative thoughts and associated feelings and actions, and cognitive restructuring to challenge and change negative thoughts. Homework assignments to enhance the cognitive restructuring skill set were provided. Session 6 elicited relationship difficulties and presented problem-solving strategies and assertive communication skills training needed to address these. A review of all coping strategies and relapse prevention ended the sixth session.
Two combined physiotherapy and psychology group sessions (1.5 hours each) devised action plans for pain flare-up and commitment to the routine of exercise, with a group review of individual plans in the second session. Two nutrition sessions (2 and 2.5 hours) with a dietitian focused on education, including food labeling and industry laws, weight management, and how nutrition affects pain management. A two-hour educational session with the occupational therapist focused on returning to normal daily activities using aids where necessary, goal setting, and pacing. Patients also had a 30-minute remedial massage to experience the benefits of this intervention. The program concluded with a discharge case conference attended by the participant and therapeutic team, at which recommendations for ongoing management were formulated and disseminated to referrers and other therapists with the participant's consent.
Statistical Analyses
Handling of Missing Data
The nature of the missing data was analyzed, and it was missing completely at random (MCAR). Thus, the mean of the completed items within the questionnaire was substituted for any missing item data, provided that the number of missing items did not exceed 10% for any individual's responses to a questionnaire; otherwise all the questionnaire data were considered missing. Any case with missing questionnaire data was not included in the analysis for that questionnaire.
Group-Level Change
The statistical significance of the mean difference scores for pre-to post-treatment for each measure was calculated using paired t tests; using G*Power, the achieved statistical power for these analyses with the sample size of 163 was 0.99, and therefore adequate [28] . Effect sizes (ESs) were then calculated in accordance with the recommendation that when the research focus is on change as assessed with a repeated measures single group design, then estimating the group effect size from test statistics using the change score metric is most appropriate [29] . Thus, the repeated measures effect size was calculated as follows: d RM ¼ t RM /ͱn, where d RM is the repeated measures ES for change scores, t RM is the repeated measures t test statistic, and N is the sample size.
Individual-Level Change
The percentage of improvement (or worsening) in pain intensity from pre-to post-treatment was calculated according to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines. Clinically meaningful individual-level change was identified using the criterion of a 30% or greater improvement [10] . This same criterion was also applied to the other outcomes, such that a 30% or greater worsening in outcome was used to classify individuals as deteriorated. Consistent with IMMPACT guidelines, ESs for individuals were calculated for all other measures as the difference between each participant's pretreatment score and post-treatment score; difference scores of at least half a standard deviation were considered clinically significant [10] . The other distribution-based method implemented for examining the clinical significance of the findings was the standard error of measurement (SEM), calculated as: SEM ¼ s v ͱ(1-r vv ), where s v is the standard deviation of the participant's pretreatment scores and r vv is the test-retest reliability of the measure. Following IMMPACT guidelines, individual change scores of at least 1 SEM in either direction were judged as clinically significant [10] .
The RCI was calculated as a conservative estimate of clinical significance that accounts for the reliability of the scale [30] . RCIs were calculated as follows:
2 , where v 1 represents a participant's pretreatment score and v 2 represents their posttreatment score. Individuals whose RCI scores exceeded þ/-1.96 (based on the 95% confidence interval [CI], or P < 0.05) were categorized as showing clinically significant change.
Group-Level Predictors of Change
Three separate multivariate analysis of variance (MANOVA) models were examined. In each of the MANOVA models, a main effects-only model was specified that tested for main effects of age, gender, pain type (nociceptive vs neuropathic), and baseline pain duration, number of pain sites, CPG pain grade, pain intensity, DASS Depression, Anxiety and Stress, and PCS on pre-to post-treatment change scores (pre-minus posttreatment score) on 1) the psychological outcomes (DASS, PCS), 2) social outcomes (OQ-45), and 3) physical outcomes (TUG, 6MWT, Grip Strength, Balance, Two-Minute Stair Climb test). Gender and pain type were included in the model as dichotomous betweensubjects factors, while the other predictors were entered as continuous variables. Gender and pain type were coded so that higher values were assigned to men and neuropathic pain (mixed pain type was coded the same as neuropathic pain in the analyses). With the study sample size of 163, adequate power (0.99) was obtained to detect a medium effect size in these MANOVA models. For all multivariate analyses, tests of the F statistic for each independent variable were examined as omnibus tests. In order to reduce the likelihood of type I error, univariate analyses of variance (ANOVAs) were only examined if the multivariate omnibus test was
significant. An ANOVA model with the same set of predictor variables was additionally examined for change in pain intensity. The assumptions for these models were checked and confirmed.
Individual-Level Predictors of Change
A binary variable was calculated to classify individuals as responders or nonresponders for each of the four methods used to evaluate clinically significant change across each of the outcome variables. Consistent with previous research [9], a participant was coded as a responder on an individual outcome variable if they met the criteria of clinically significant change for at least one method, while showing no deterioration on any other classification method. Participants who showed no change across all methods for establishing clinical significance or who showed deterioration on at least one method of classification were coded as nonresponders. The percentage of participants classified as responders or as nonresponders across all measures was calculated, and the clinical and demographical characteristics of these groups was reported. Logistic regression was then conducted with the predictor variables of age; sex; pain grade; pain duration; number of pain sites; pain type; and baseline pain intensity, pain catastrophizing, depression, anxiety, and stress. The computed binary variable was the dependent variable for all regression models. For the logistic regression models conducted using several continuous, normally distributed independent variables, at conventional alpha and power levels of 0.05 and 0.8, respectively, the study sample size of 163 was adequately powered to detect an odds ratio lower than 0.6 and higher than 1.8.
Results
Sample Characteristics
A small majority of participants were female (58%). The mean age of the sample was 48 years (SD ¼ 15 years, range ¼ 18-89 years). Most participants (74%) had high disability and severe limitations from their pain, classified as grade IV pain by the Chronic Pain Grade Questionnaire [11] . Based on medical chart review, the median pain duration was 5.4 years, and most people reported one (61%) or two (19%) primary pain sites. The primary pain-related diagnoses reported were degenerative spinal disorder (41%), osteoarthritis (17%), complex regional pain syndrome (CRPS; 17%), primary headache pain (12%), musculoskeletal soft tissue and muscle pain (11%), back pain (10%), and other types (e.g., rheumatoid arthritis, fibromyalgia, ankylosing spondylosis) (16%). Type of pain was classified by the admitting rehabilitation physician and was medical chart verified by a second physician as neuropathic (27%), nociceptive (17%), or mixed (56%). At program entry, 44% of participants were using opioid medications, 47% paracetamol, 26% nonsteroidal anti-inflammatory drugs, and 36% used anti-epileptics as analgesic medication. In addition, more than half of the sample (56%) had been prescribed one or more antidepressant medications (e.g., Selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclics), and 28% of participants took benzodiazepine medication. Other previous interventions included 40% of participants who had tried spine, joint, or facet injections (e.g., with steroids), 33% who had previously had surgical procedures (e.g., laminectomy, spinal fusion), 2% who had implanted spinal cord stimulators, and 1% who wore a brace.
Group-Level Change from Pre-to Post-Treatment Table 1 shows the mean pre-and post-treatment values, SDs, and sample size for each measure assessed, along with t test scores and effect sizes. Change in pain intensity was not significant. For all psychological outcomes, statistically significant group-level change was observed (Ps < 0.001), with effect sizes ranging from small for DASS Anxiety to medium for DASS Depression, DASS Stress, and PCS. All OQ-45 social outcomes significantly improved (Ps < 0.01), except for the Interpersonal Distress scale (P ¼ 0.11); however, effect sizes were small. All physical outcome measures showed statistically significant group-level change (Ps < 0.001), with effect sizes ranging from small for the left OLS test to large for the 6MW test.
Individual-Level Change from Pre-to Post-Treatment
The percentage of participants who deteriorated, remained stable, or improved as evaluated by each of the four methods for establishing clinically meaningful individual-level change is shown in Table 2 ; the RCI results are reported according to the 95% confidence interval. The most consistently improved outcomes across each of the methods were DASS Depression, DASS Anxiety, DASS Stress, PCS, TUG, 6MW, and the Two-Minute Stair Climb. In general, across virtually all measures and classification methods, approximately half of participants showed clinically meaningful improvement, while less than 10% showed deterioration. The remainder of participants were not significantly changed at the conclusion of the program.
Group-Level Predictors of Change
The first MANOVA model tested for age, gender, pain type, number of pain sites, and baseline pain duration, CPG pain grade, pain intensity, DASS Depression, Anxiety, and Stress, and PCS group-level differences in pre-to post-treatment changes in the psychological outcomes (DASS Depression, Anxiety, and Stress and PCS). The MANOVA omnibus test indicated a significant multivariate main effect for baseline DASS depression (Wilk's k ¼ 0.45, F(4,120) ¼ 36.08, P < 0.001), anxiety (Wilk's k ¼ 0.49, F(4,120) ¼ 31.60, P < 0.001), and stress (Wilk's k ¼ 0.56, F(4,120) ¼ 23.32, P <0 .001), as well as PCS (Wilk's k ¼ 0.69, F(4,120) ¼ 13.69, P < 0.001). No main effect was found for the other independent variables. Follow-up ANOVAs were examined to determine the nature of the multivariate effect in regards to the specific pre-to posttreatment changes in psychological outcomes. Those higher in baseline depression, stress, and pain catastrophizing, respectively, showed greater treatmentrelated reductions in depression (F ¼ 53.42, P < 0.001), stress (F ¼ 27.66, P < 0.001), and pain catastrophizing (F ¼ 37.32, P < 0.001). Baseline anxiety, on the other hand, was associated with all psychological outcomes; specifically, those higher in baseline anxiety showed greater treatment-related reductions in depression (F ¼ 6.29, P ¼ 0.01), anxiety (F ¼ 26.59, P < 0.001), stress (F ¼ 5.47, P ¼ 0.02), and pain catastrophizing (F ¼ 12.44, P ¼ 0.001).
The second MANOVA model tested for the same set of predictors as in model 1, in relation to social-related outcome variables as assessed by the OQ-45. However, the MANOVA omnibus tests indicated no significant main effects (Ps < 0.30); therefore, ANOVAs were not examined. The third MANOVA tested for group-level differences in these same independent variables on physical outcome measures (TUG, 6MWT, Grip Strength, Balance, Two-Minute Stair Climb test). The MANOVA omnibus test indicated a significant multivariate main effect for pain duration only (Wilk's k ¼ 0.72, F(7,81) ¼ 4.47, P < 0.001). Follow-up ANOVAs showed that those entering the program who had experienced pain for a longer duration showed greater improvement on the TUG (F ¼ 22.45, P < 0.001). A final ANOVA model was conducted to investigate group-level differences in pre-to postprogram change in pain intensity using the same set of independent variables. Treatment-related improvement in pain intensity was associated with older age (F ¼ 10.78, P ¼ 0.001), neuropathic pain type (F ¼ 8.14, P < 0.01), higher baseline pain intensity (F ¼ 19.39, P < 0.001), and lower baseline anxiety (F ¼ 8.00, P < 0.01).
Individual-Level Predictors of Change
Logistic regression analyses found that across the psychological, social, and physical outcomes, CPG pain grade, baseline pain duration, number of pain sites, pain type, pain intensity, DASS Depression, DASS Anxiety, DASS Stress, and PCS significantly predicted responder status on at least one criterion variable. Specifically, those participants with a lower CPG pain grade entering treatment were more likely to improve their balance on their right leg (odds ratio [OR] ¼ 0.42; 95% CI ¼ 0.19-0.96; P ¼ 0.04). A higher number of pain sites entering treatment was also associated with improved right leg balance (OR ¼ 2.22; 95% CI ¼ 1.31-3.76; P < 0.01); however, those with fewer pain sites were more likely to improve on OQ-45 social functioning (OR ¼ 0.51; 95% CI ¼ 0.31-0.86; P ¼ 0.01). Longer pain duration and lower current pain intensity entering the program both predicted a greater probability of decreased anxiety during treatment (OR ¼ 1.07; 95% CI ¼ 1.00-1.14; P ¼ 0.04; and OR ¼ 0.71; 95% CI ¼ 0.56-0.89; P < 0.01, respectively). Nociceptive The total number of measures for which an individual was classified as a responder (i.e., where clinically significant change for at least one classification method was observed while no deterioration on any other classification method was observed) vs nonresponder (i.e., where no change across all classification methods was observed or where deterioration on at least one method of classification was observed) was calculated and is shown in Table 3 . More than one-third of the individuals in the sample (34%) were classified as multidomain responders, that is, responders on at least one measure across each of the psychological, social, and physical domains. Table 4 shows the clinical and demographic characteristics of those individuals who were responders on five or fewer measures vs six to 10 measures vs more than 10 measures.
A logistic regression model was conducted to examine the predictors of overall responsiveness across measures. Given that only five participants were responders on more than 10 measures, these individuals were grouped in with those participants who were responders on six to 10 measures, and this group was compared with those participants who were responders on five or fewer measures, and the set of predictors was examined. were significantly associated with overall program responder status across measures (Ps > 0.05). A final logistic regression model was conducted to examine predictors of multidomain responders (vs responders on one or two measurement domains only). Those participants who were older were more likely to improve across all outcome domains (OR ¼ 1.04; 95% CI ¼ 1.00-1.08; P ¼ 0.03); no other predictors were significant in this model (Ps > 0.05).
Discussion
In the context of rising prevalence rates and costs of chronic pain, the question arises of who is most likely to benefit from resource-intensive IPM programs. Heterogeneity of individual responses to chronic pain treatment is well recognized [31] . However, few studies have thoroughly examined individual-level predictors of response using the currently recommended responder classification methods [10] . The current results showed that while the IPM program was generally effective across a range of psychosocial and physical outcomes, there was substantial individual-level variability in responsiveness. Some of this individual-level variability could be accounted for by baseline differences, particularly in depressive mood, as well as by pain type (i.e., nociceptive vs neuropathic pain) and age; this information could help select patients more likely to benefit from IPM programs.
The results also confirm that the overall group-level effectiveness of an IPM program in a community private practice-based setting is comparable with what has been reported within meta-analyses and other studies [3] [4] [5] . Each of the psychological and physical outcomes showed significant improvement, as did the social functioning outcomes, with the exception of a measure of interpersonal distress. The largest group-level effect sizes were found on the physical outcome domain, particularly functional mobility and exercise capacity, which were targeted within the physiotherapy component of the program. As in other studies examining IPM programs [1, 9, 32, 33] , pain intensity did not show significant improvement, possibly because a primary emphasis of most IPM programs is to reduce pain medications and better cope with the effects of pain on function, rather than address pain pathology. However, the observed modest reductions in pain intensity are comparable not just with those reported with other IPMs, but also with those reported for pharmacological and procedural treatment modalities [34] .
The problem, however, with group-level outcome statistics is that they mask the substantial treatment-related gains made by some participants, the lack of change for others, and the deterioration of outcomes for another subgroup by lumping all of these response categories together in an overall average. The individual-level responder results of the current study showed that the extent of individual improvements was larger than that of deterioration in almost every instance. The largest individual-level improvements were observed for functional mobility, exercise capacity, and aerobic endurance, and for the key psychological domain outcomes of depression, anxiety, stress, and pain catastrophizing. This is consistent with the group-level analyses and reflects the emphasis on physiotherapy and psychological therapy in the program. Conversely, there was minimal program content directly addressing social functioning, and the outcome of this domain was correspondingly poorer. Thus, if social-related outcomes are key areas of concern, then they need to be specifically targeted therapeutically.
Although recommended, very few other studies examining IPMs have examined objective performance measures such as those used in the present research [35] .
A previous study found that fewer individuals show improvement on objective functional measures compared with self-report measures [36] . However, our results showed significant improvements across both objective and self-report outcomes. Future research comparing IPM outcomes across assessment modalities over time is needed in order to more reliably understand the individual-level outcomes most likely to be effectively targeted by IPMs.
The second aim of the study was to examine patientrelated factors that could predict IPM outcome. A recent review of the mixed results reported in the literature identified a trend: that poor cognitive coping at baseline is associated with worse treatment outcome [8] .
However, in the current study, higher depression, stress, and pain catastrophizing scores predicted better group-level improvement on these same outcomes. This finding is consistent with a recently proposed moderation theory that a primarily cognitive behavioral theoryoriented IPM such as the one reported here (as opposed to, for example, a program emphasizing mindfulness) may be particularly helpful for individuals in need of limiting these maladaptive cognitive coping outcomes [8].
The group-level findings regarding the predictive capacity of baseline anxiety were more robust as-unlike the findings regarding depression, stress, and pain catastrophizing-the predictive capacity of anxiety extended beyond treatment-related improvement in this same construct. Higher anxiety at baseline predicted greater improvement not only in anxiety during treatment, but also predicted greater improvement in depression, stress, and pain catastrophizing. Change in pain intensity was the only outcome where lower baseline anxiety was associated with group-level improvement. This finding supports the use of population-level screening of anxiety in the context of pain as a gross indicator of suitability for an IPM.
Although most studies have not found a relationship between demographic variables, baseline pain duration, number of pain sites, and pain type, these variables have been theorized to be of importance and were therefore examined in this study [37, 38] . In our grouplevel analysis, older age, higher baseline pain intensity, and neuropathic pain type all predicted improved pain intensity outcome, while longer pain duration predicted more improvement in the measure of functional mobility. While useful at a population level, the same limitations of the group-level effectiveness estimates apply to group-level predictors of response, in that by averaging across individuals who improved, remained stable, and deteriorated (i.e., by examining predictors of pre-to post-treatment change scores), identification of patient characteristics associated specifically with clinically meaningful improvement may be obscured. Some of the differences in patterns of outcomes across the group-and individual-level predictor analyses may be examples of this masking.
In this study, we replicated and extended the approach employed by Fedoroff et al. and examined multiple predictors of individual response by collapsing across the four methods of identifying clinically meaningful change and classified only those individuals who showed improvement across at least one method-with no deterioration across any other method-as responders on each given outcome [9] . Logistic regression was then used to precisely identify baseline characteristics of these individuals that are associated with increased likelihood of meaningful benefit from an IPM program. Of the clinically significant findings that emerged in these individual outcome analyses, the baseline characteristic that most consistently predicted improvement across all three domains of functioning-psychological, social, and physical-was depression. Those individuals who endorsed more depressive symptoms entering the program benefited the most. Thus, although a number of pain-related variables (including disability, number of pain sites, pain duration, and intensity) contributed to outcomes, these results suggest that individuals who are experiencing depression may benefit most from an IPM.
However, chronic pain is not well defined by one particular outcome, as most individuals are affected across many systems and heterogeneity of treatment effects across outcomes is the norm, not the exception [39] . Thus, the overall purpose of this study was to establish how well our IPM targeted multiple domains of functioning and what factors might be associated with response across the psychological, social, and functional domains. Results showed that more than 40% of the sample was classified (using stringent multiple responder classification methods) as showing meaningful response on six or more of the outcome measures. The most significant differentiating predictor of overall program response across measures was pain type; individuals with nociceptive pain type were more than four times more likely to be classified as multi-outcome program responders than those individuals with neuropathic pain. This is consistent with past research identifying the neuropathic pain type as the most recalcitrant to treatment [40, 41] .
In terms of multidomain responders, approximately onethird of the sample improved on at least one measure across each of the psychological, social, and physical domain outcomes. This multidomain response was predicted by participant age, with those individuals who were older being significantly more likely to show improvement across all three domains. This finding is particularly pertinent given that the incidence of chronic pain is most commonly found to increase with age, as well as the context of longer life expectancies and the aging populations of many developed countries [42, 43] . Although the reasons for age emerging as a predictor of multidomain response cannot be elucidated from the present data, these results suggest that IPM programs may represent a particularly useful approach for maintaining independent living and optimizing quality of life in older aged populations with chronic pain.
Limitations and Future Directions
This study was conducted in a community-based private clinical setting; hence, there was no control condition, and no randomization of treatment or order of assessment administration was possible. As reported in the Sample Characteristics section, the population served by this clinic tends to be highly disabled and to exhibit poor overall functioning. A striking example is that this clinic receives a high proportion of referrals for individuals with a diagnosis of CRPS. Seventeen percent of the individuals in of our sample were referred with CRPS as the identified primary source of pain, which is substantially higher than the 2.6% incidence rate reported by de Mos and colleagues from data in the Netherlands and the lower than 1% incidence reported by Sandroni and colleagues from data collected in the United States [44, 45] . Further, a large proportion had experienced several other failed interventions, and almost all were receiving multiple medications for relief of pain and its associated effects; a limitation of this study is that possible changes in these medications during the IPM were not controlled for as a potential confound.
Although an important future direction, it was not possible to investigate factors associated with premature termination in this study because ethics approval was such that if a participant withdrew, consent to use any of the data collected prior to withdrawal was also withdrawn. As the majority of pain management programs in Australia run in private practice, it is difficult to recall patients for follow-up assessments unless they are rereferred for clinical reasons. Future research within such practice settings that includes longer-term follow-up assessments for all individuals who drop out as well as those who complete the program is needed in order to examine long-term relapse and maintenance patterns and predictors of post-treatment outcome trajectories over time. This evidence would help optimize maintenance interventions that are stratified by risk level for relapse. Finally, some of the logistic regression models may have been influenced by insufficient statistical power, inflating the risk of type I error. Replication of this approach to examine the predictors of multioutcome response with a larger sample size is needed.
Conclusions
In Australia, approximately 3.2 million people live with chronic pain [46] , which costs $34.3 billion annually in direct health care expenses, disease burden, and lost productivity [47, 48] . Other developed countries report similar incidences and proportionate costs [49, 50] . Unfortunately, all of these figures are underestimates as chronic pain is underdiagnosed and undertreated [51, 52] . When health care resources are failing to meet the demand of an ever-increasing number of people living with chronic pain, there is a critical need to advance our capacity to match individuals to the treatments most likely to be efficient and effective across a range of important functional outcomes. The present study highlights the shortcomings of applying group-level analyses to the individual experience and treatment of chronic pain, as well as the problem of simply examining statistical significance in the absence of clinical significance.
We demonstrated by comparing the results found from group-level vs individual-level analysis that examination of individual-level, clinically meaningful change adds substantially to the understanding of IPM response, beyond that afforded by group-level analyses. The practice-based evidence of this study showed, using the most stringent of responder criteria employed in the literature to date, the constellation of factors that are associated with IPM response and identified potential individual-level patient characteristics that predicted who is most likely to benefit. Although the results need to be replicated, this study found that initially high baseline depression entering the program was a clinically reliable individual-level predictor of improvement on a number of outcomes. However, clinically meaningful multi-outcome response on six or more measures was most likely for those individuals presenting with nociceptive pain type. Additionally, the International Association for the Study of Pain highlights the critical need for IPM programs to target multiple domains of physical, psychological, work, and social functioning; this study showed that this targeted multidomain response may be most readily achievable for those individuals commencing an IPM program who are older aged [53] . Further research is needed to identify why the mechanisms underlying neuropathic pain are so refractory to treatment [54] , and to then devise IPM strategies to target these mechanisms more effectively.
